The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Fecal Microbiota Transplantation for Treatment of Parkinson Disease: A Randomized Clinical Trial
Open accessAbstract
Importance: Dysbiosis has been robustly demonstrated in Parkinson disease (PD), and fecal microbiota transplantation (FMT) has shown promising effects in preclinical PD models. Objective: To assess the safety and symptomatic efficacy of colonic single-dose anaerobically prepared FMT. Design, Setting, and Participants: This was a double-blind, placebo-controlled, randomized clinical trial conducted between November 2020 and June 2023 with a follow-up period of 12 months at 4 hospitals in Finland. Patients with PD aged 35 to 75 years in Hoehn & Yahr stage 1-3 with a mild to moderate symptom burden and dysbiosis of fecal microbiota were included. Of 229 patients screened, 48 were randomized and 47 received the intervention. One patient discontinued due to worsening of PD symptoms. Two further patients were excluded before analysis and 45 were included in the intention-to-treat analysis. Intervention: Participants were randomized in a 2:1 ratio to receive FMT or placebo via colonoscopy. Main Outcomes and Measures: The primary end point was the change of Movement Disorder Society Unified Parkinson’s Disease Rating Scale parts I-III (part III off medication) at 6 months. Safety was assessed by recording adverse events (AEs). Results: The median (IQR) age was 65 (52.5-70.0) years in the placebo group and 66 (59.25-69.75) years in the FMT group; 9 (60.0%) and 16 (53.3%) patients were male in the placebo group and the FMT group, respectively. The primary outcome did not differ between the groups (0.97 points, 95% CI, −5.10 to 7.03, P = .75). Gastrointestinal AEs were more frequent in the FMT group (16 [53%] vs 1 [7%]; P = .003). Secondary outcomes and post hoc analyses showed stronger increase of dopaminergic medication and improvement of certain motor and nonmotor outcomes in the placebo group. Microbiota changes were more pronounced after FMT but differed by donor. Nevertheless, dysbiosis status was reversed more frequently in the placebo group. Conclusions and Relevance: FMT was safe but did not offer clinically meaningful improvements. Further studies—for example, through modified FMT approaches or bowel cleansing—are warranted regarding the specific impact of donor microbiota composition and dysbiosis conversion on motor and nonmotor outcomes as well as medication needs in PD. Trial Registration: ClinicalTrials.gov Identifier: NCT04854291
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There are currently four RCTs with available evidence for the role of FMT in treating PD [206–209].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [206]
In the citing paper
“Three of these reported changes in global or motor function, and of these two reported significant improvement UPDRS PD symptom scores at 12 weeks and 12 months, respectively.”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [206]
In the citing paper
“One study reported no changes in motor function at 6 months post-FMT, although here the treatment group required smaller dose increases than placebo.”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [206]
In the citing paper
“In these studies, the clinical findings were associated with a shift toward anti-inflammatory microbial species.”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [206]
In the citing paper
“In this study, only 3% of the treatment group were reported to show a change from dysbiotic to non-dysbiotic status, compared to 33% in the placebo arm, suggesting that the FMT treatment failed to produce a significant change in the gut microbiome.”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [206]
In the citing paper
“In this study, only 3% of the treatment group were reported to show a change from dysbiotic to non-dysbiotic status, compared to 33% in the placebo arm, suggesting that the FMT treatment failed to produce a significant change in the gut microbiome.”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [206]
Citations
Cites
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53221.x · Cited by 25,553
Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez‐Martin, P., Poewe, W., Sampaio, C., Stern, M. B., Dodel, R., et al. (2008) · Movement Disorders · doi:10.1002/mds.22340 · Cited by 7,536
Gut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968
Self-citationFRANCIS, C. Y., MORRIS, J., & WHORWELL, P. J. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.142318000.x · Cited by 1,708
Lai, E. J., Calderwood, A. H., Doros, G. D., Fix, O. K., & Jacobson, B. C. (2009) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2008.05.057 · Cited by 1,322
European consensus conference on faecal microbiota transplantation in clinical practice
Cammarota, G., Ianiro, G., Tilg, H., Rajilić-Stojanović, M., Kump, P., Satokari, R., Sokol, H., Arkkila, P., Pintus, C., Hart, A., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-313017 · Cited by 1,207
Self-citationSun, M.-F., Zhu, Y.-L., Zhou, Z.-L., Jia, X.-B., Xu, Y.-D., Yang, Q., Cui, C., & Shen, Y.-Q. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.02.005 · Cited by 736
Zhao, Z., Ning, J., Bao, X.-Q., Shang, M., Ma, J., Li, G., & Zhang, D. (2021) · Microbiome · doi:10.1186/s40168-021-01107-9 · Cited by 616
Aho, V. T. E., Houser, M. C., Pereira, P. A. B., Chang, J., Rudi, K., Paulin, L., Hertzberg, V., Auvinen, P., Tansey, M. G., & Scheperjans, F. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00427-6 · Cited by 435
Self-citationThe microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic
Tan, A. H., Lim, S. Y., & Lang, A. E. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00681-2 · Cited by 392
Cited by
Sorted by citations
Items 101–128 of 128
Sun, G., Liu, W., Tu, Y., Liu, Q. Y., & 冯美江 (2026) · Journal of Radiation Research and Applied Sciences · doi:10.1016/j.jrras.2026.102564
Liang, B., Zou, J., Mao, X., Xie, N., & Zhaohui, L. (2026) · Revista de Neurología · doi:10.31083/rn50106
Sharma, S. A., & Patri, M. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01924-7
Noor, U., Khan, I., Zheng, W.-F., Khan, I., & Li, S. (2026) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2026.06
Fecal microbiota transplantation in Parkinson’s disease: a systematic review
Eissazade, N., Mosavari, H., Eghdami, S., Rohani, M., Fereshtehnejad, S., & Khoeini, T. (2026) · Neurodegenerative Disease Management · doi:10.1080/17582024.2026.2715585
Balsamo, J. M., & Bess, E. N. (2026) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.6c00110
Li, Q., Ding, X., Zhang, S., & Zhang, F. (2026) · Microbiota Medicine Research · doi:10.1002/mmr3.70013
Kumari, A., & Aran, K. R. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01978-7
The gut microbiota as a new therapeutic target in the treatment of neuropsychiatric disorders
Shtemberg, L. V., & Selimova, R. (2026) · Vrach · doi:10.29296/25877305-2026-08-04
Microbiome and Diseases: Gut–Brain Axis and Neurological Disorders
de Castilhos, J., & Stein‐Thoeringer, C. K. (2026) · Springer eBooks · doi:10.1007/978-3-032-26410-7_18
Porwal, M., Malviya, R., Chandra, P., Sridhar, S. B., Shareef, J., Wadhwa, T., Tripathy, D. B., & Arockiam, D. (2026) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2026.579099
Silva-Olivares, F., Vidal-Herrera, N., Acevedo-Hernández, P., Rabbia, V., Petermann-Rocha, F. E., Thomas‐Valdés, S., & Jorquera, G. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1869929
Mazzuoli‐Weber, G., & Elfers, K. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1909617
Mingke, T., Li, J., Zhang, C., Tu, R., & Wang, S. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1973833
Hasanuzzaman, M., Bang, C. S., Lee, J. J., & Gong, E. J. (2026) · Journal of Korean Medical Science · doi:10.3346/jkms.2026.41.e335
Koterba, M., Skiba, A., Kler, A., Błaszczyk, K., Woźny, M., Stefaniak, O., & Nowicka, J. (2026) · Biomedicines · doi:10.3390/biomedicines14102256
Zucchi, E., Niccolai, E., Maio, F. D., Costantini, R. C., Quaranta, G., Guarnaccia, A., Bibbò, S., Martinelli, I., Gianferrari, G., Simonini, C., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106509
Scheperjans, F., Borghammer, P., Pfeiffer, R. F., Appel‐Cresswell, S., & Keshavarzian, A. (2026) · Movement Disorders · doi:10.1002/mds.70566
Self-citationBeyond the brain: Neurology, the gut, and a gap in training
Demas, A. (2026) · Revue Neurologique · doi:10.1016/j.neurol.2026.09.007
Lin, W., Shu, Z., Liu, G., Fang, J., & Ding, S. (2026) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-026-11246-w
From gut microbiome to aging brain: Butyrate as a neurogeroscience effector
Mitrea, L., Calinoiu, L.-F., Martau, G.-A., Teleky, B.-E., Cocean, A.-M., Odocheanu, R., Stefanescu, B.-E., & Vodnar, D.-C. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.107037
Gries, M., Schäfer, K., & Endres, K. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2748747
Emerging links between gut dysbiosis, aryl hydrocarbon receptor activation, and Parkinson’s disease
Aziz, N. F., & Kortagere, S. (2026) · Communications Biology · doi:10.1038/s42003-026-11156-1
Liu, X., Wang, S., Long, W., Tan, X., Li, W., & Gao, L. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1926883
Yang, X., Li, Y., Hu, Q., Pan, X., Hong, J., & Li, L. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1907410
The Microbiota-Gut-Brain Axis in Neurological and Neuropsychiatric Disorders: A Literature Review
Brar, H., Do, N., Kelser, C., Pattipati, S. N., & Nalamolu, K. R. (2026) · Cureus · doi:10.7759/cureus.118684
wu, C., Guo, L., Sun, X., 朱金璞, Zhao, Z., Qi, S., Li, Y., Li, H., Zhao, R., Xiu, Z., et al. (2026) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(26)61221-6
Metadata
- Authors
- Scheperjans, F., Levo, R., Bosch, B., Lääperi, M., Pereira, P. A. B., Smolander, O.-P., Aho, V. T. E., Vetkas, N., Toivio, L., Kainulainen, V., Fedorova, T. D., Lahtinen, P., Ortiz, R., Kaasinen, V., Satokari, R., & Arkkila, P.
- Affiliations
- University of Helsinki (FI)
- Helsinki University Hospital (FI)
- Lääperi Statistical Consulting, Helsinki, Finland
- Aarhus University (DK)
- Päijät-Hämeen Keskussairaala (FI)
- Tampere University Hospital (FI)
- University of Turku (FI)
- Corresponding author
- Scheperjans, Filip
- ORCID
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2024-09-01
- Volume
- 81
- Issue
- 9
- Pages
- 925
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W4401075949
- Cited by
- 128
- References
- 47
- Citations by year
- 2026: 58 · 2025: 60 · 2024: 10
- FWCI
- 34.25
- Type
- journal article
- Language
- en
- Open access
- green
- pmc.ncbi.nlm.nih.gov
- Locations
- JAMA Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- Tampere University Institutional Repository (Tampere University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- fecal microbiota transplantation, Parkinson's disease, gut dysbiosis, microbiota, MDS-UPDRS, motor symptoms, non-motor symptoms, dopaminergic therapy, gastrointestinal adverse effects, donor microbiota, treatment safety, treatment efficacy, bowel preparation
- MeSH terms
- Fecal Microbiota Transplantation, Adult, Aged, Double-Blind Method, Female, Humans, Male, Middle Aged, Parkinson Disease, Treatment Outcome, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
